Living well during hormonal treatment
WISH is exploring how women receiving hormonal treatment after early breast cancer can be better supported throughout follow-up closer to home, while remaining connected with their oncology team.
Why this matters
Hormonal treatment is a long journey
Hormonal treatment, also called endocrine therapy, is an important part of care for many women with hormone-receptor-positive breast cancer. It is usually continued for several years after initial treatment to help reduce the risk of the cancer returning.
During this time, women may experience changes in their physical, emotional and social wellbeing. Regular follow-up is therefore important not only to monitor treatment, but also to understand how women are feeling and what support they may need.
Every woman’s experience is different
WHAT CAN MATTER DURING FOLLOW-UP?
Help us shape better follow-up – join the WISH Patient Board
We want women’s experiences and perspectives to help shape WISH throughout the project. We are inviting women with experience of early breast cancer and hormonal treatment to join our WISH Patient Board.
As a member, you may be invited to share your views on the follow-up model, digital tools, patient information, communication materials and other project activities. Your input will help us make WISH more relevant, understandable and responsive to women’s needs.
Interested in joining or learning more? Contact us — we would be very happy to hear from you.
FAQs
Is WISH a new breast cancer treatment?
No. WISH does not develop a new cancer medicine. It is studying a new way of organising and supporting follow-up during hormonal treatment.
Will WISH replace my oncologist?
No. WISH is designed around shared care. Oncology teams remain involved and available when specialist input is needed.
Is the WISH platform already available?
Not yet. The platform is currently being developed and will be evaluated as part of the project.
Can I take part in the WISH study?
Yes. Recruitment has not yet started. Information about participating centres, eligibility and recruitment will be published after the required clinical and ethical approvals..